Atomo Investor Webinar Presentation
Released
Released
Announcement PDF
28th January 2025
ASX Announcement
Atomo Investor Webinar Presentation
SYDNEY Australia, 28 January 2025 –Atomo Diagnostics Limited (ASX: AT1) (Atomo or the
Company) will release its Q2 FY25 Results on Thursday 30th January 2025
A results briefing webinar for analysts and investors, hosted by Managing Director & CEO,
John Kelly will be held on Thursday 30th January 2025 at 1.30pm (AEDT).
To access the webinar please pre-register by clicking this link.
Please submit any questions in advance of the webinar commencing to:
investorqueries@atomodiagnostics.com
~ ENDS ~
For more information, please contact:
John Kelly
Managing Director & CEO
e. john.kelly@atomodiagnostics.com
p. +61 401 922 279
Investor Queries
investorqueries@atomodiagnostics.com
This announcement was authorised by the Managing Director & CEO on behalf of the Board.
About Atomo
Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid
diagnostic test (RDT) devices to the global diagnostic market.
Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability
across rapid point-of-care (POC) and at-home testing applications. The Company has successfully
commercialised a number of products across international markets and has supply agreements in place
for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial
differentiation and female health. See more at www.atomodiagnostics.com
Atomo Diagnostics Limited
ACN 142 925 684
Level 1, 3-5 George St Leichhardt NSW 2040
Share your feedback
Discover